Abstract 471TiP
Background
Neurokinin-1 (NK-1) receptor antagonists will prevent CINV effectively but are not affordable for patients of low socioeconomic status and there is still an unmet need for the prevention of CINV in the low socio-economic setting. Recent studies show olanzapine which blocks multiple neurotransmitters in the brain is also effective in preventing CINV and pregabalin which inhibits the release of neurotransmitters is effective in preventing postoperative nausea and vomiting. A mechanistic synergism is expected between the olanzapine and pregabalin combination. Therefore, this trial was designed to evaluate the add-on combination of olanzapine and pregabalin in the management of CINV.
Trial design
This trial is a group sequential response adaptive randomized double-blinded clinical trial. The O'Brien-Fleming boundaries were defined for efficacy and futility. The total sample size to achieve the primary objective of the difference in the proportion of patients with “overall no nausea” was calculated to be 84, with an allocation ratio of 1:1. Depending on the results of each interim analysis, the allocation ratio will be changed, and more patients will be allocated to the well-performing arm. In our study, we enrolled cancer patients belonging to low socio-economic status who planned to receive highly emetogenic cancer chemotherapeutic agents and the standard of care antiemetic premedication (ondansetron 8mg and dexamethasone 8mg). Patients received either olanzapine 5 mg plus pregabalin 75 mg orally or a matching placebo daily on day 1 through day 5 in addition to their standard antiemetic premeditations. In stage one of the trial, 30 patients were equally randomized into two groups and the interim analysis showed the experimental group performed better in terms of “overall no nausea” (40% vs. 6.6 % p value-0.042). However, it didn't breach the boundary (0.0035) fixed by the O'Brien and Fleming approach. So, the trial is being continued to the second stage. As the Z (1.73) value was between 1.5-2, the allocation ratio has been changed to 2:1 for the next stage of the trial as per the protocol.
Clinical trial identification
CTRI/2021/08/035451.
Legal entity responsible for the study
The authors.
Funding
Indian Council of Medical Research (ICMR), India.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
Presenter: Zhiqiang Wang
Session: Poster Display
Resources:
Abstract
112P - Optimal classification and treatment strategy based on technical and oncological futures in recurrence of colorectal liver metastases
Presenter: Kosuke Kobayashi
Session: Poster Display
Resources:
Abstract
113P - Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Presenter: Kai Ou
Session: Poster Display
Resources:
Abstract
114P - The prognostic role of LAG-3 expression in metastatic colorectal cancer
Presenter: Yi-Hsuan Huang
Session: Poster Display
Resources:
Abstract
115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
Presenter: Meng-Che Hsieh
Session: Poster Display
Resources:
Abstract
116P - Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
117P - Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)
Presenter: Vanessa Wong
Session: Poster Display
Resources:
Abstract
119P - Neoadjuvant chemoradiotherapy in the mode of hypofractionation in locally advanced rectal cancer: Is it time to change standards of care?
Presenter: Abror Abdujapparov
Session: Poster Display
Resources:
Abstract
120P - Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital
Presenter: Xiaolin Yang
Session: Poster Display
Resources:
Abstract
121P - Single-cell sequencing reveals the role of Treg cells with high expression of BIRC3 in regulating the progression of colorectal cancer
Presenter: Yuqiu Xu
Session: Poster Display
Resources:
Abstract